Update on therapeutic options for multiple sclerosis

Abstract

Multiple sclerosis (MS) is one of the most common neurologic disorders that affects young people. The disorder has long been associated with clinical relapses and a disabling course. However, there has been a rapid expansion in the available treatment options for MS, and new insights into existing therapies, as decades of research has begun to produce tangible treatment results leading to newly approved an emerging therapies.

Keywords: Alemtuzumab (Lemtrada); BG-12 (Tecfidera); Fingolimod (Gilenya); McDonald criteria; Natalizumab (Tysabri); Teriflunomide (Aubagio); Vitamin D.